Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Prostatic Neoplasms 13Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Glioblastoma 4Colorectal Neoplasms 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Disease 3Carcinoma, Hepatocellular 3Carcinoma 3Ureteral Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2

Interventions

Cisplatin 5Radiotherapy 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Cetuximab 3Carboplatin 3pembrolizumab 2Taxes 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Platinum 2Docetaxel 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1dehydroftorafur 1Tretinoin 1Surgical Procedures, Operative 1Radiation 1Neoadjuvant Therapy 1Drug Therapy 1Adjuvants, Pharmaceutic 15-fluoro-3-pyridinecarboxylic acid 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Hypopharyngeal Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05721755 2026-05-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
290 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07441681 2026-05-04

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NRG Oncology

Phase 3 Not yet recruiting
454 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡